Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to give your formal agreement (consent) to take part in the study.
- You are currently using inhaled treprostinil (a medication breathed in through an inhaler).
- You have been diagnosed with a type of lung scarring or inflammation condition called Interstitial Lung Disease (ILD), confirmed by a detailed lung scan (HR-CT), including specific types such as idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, or ILD linked to a connective tissue disease with reduced lung capacity.
- You have been confirmed to have high blood pressure in your lungs (pulmonary hypertension), diagnosed through a procedure where a thin tube is used to measure pressure in the heart and lungs (right heart catheterization).
- You are able to walk at least 100 metres during a timed 6-minute walking test.
Who may not be able to join:
- You have been diagnosed with certain specific types of pulmonary hypertension (classified as Group 1, 2, 4, or 5), such as pulmonary arterial hypertension or hypertension caused by heart or blood clot problems (confirm with trial site).
- Your underlying lung disease got significantly worse in the 28 days before joining the study.
- You started a pulmonary rehabilitation programme (structured exercise and breathing programme) within the 28 days before joining the study.
- You need more than 10 litres per minute of supplemental oxygen while at rest.
- You have previously tried and not tolerated, or not responded to, a medication called mosliciguat or similar medications in the same drug family (sGC stimulators or activators).
- You have taken part in another experimental treatment study, or received an experimental therapy, within the past 42 days or within 5 half-lives of that treatment (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ubaldo Martin, MD, Pulmovant, Inc.
Phone: +1-919-462-1310
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.